Rhythm Pharmaceuticals, Inc.
RYTM
$90.51
$3.133.58%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 11.61% | 5.76% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 11.61% | 5.76% | |||
| Cost of Revenue | -12.68% | -0.79% | |||
| Gross Profit | 14.52% | 6.61% | |||
| SG&A Expenses | 9.64% | 14.10% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 0.35% | 10.82% | |||
| Operating Income | 10.62% | -16.24% | |||
| Income Before Tax | 9.96% | -14.04% | |||
| Income Tax Expenses | -127.93% | -67.06% | |||
| Earnings from Continuing Operations | 10.21% | -13.45% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 10.21% | -13.45% | |||
| EBIT | 10.62% | -16.24% | |||
| EBITDA | 10.62% | -16.55% | |||
| EPS Basic | 10.85% | -8.73% | |||
| Normalized Basic EPS | 10.80% | -9.62% | |||
| EPS Diluted | 10.85% | -8.73% | |||
| Normalized Diluted EPS | 10.80% | -9.62% | |||
| Average Basic Shares Outstanding | 0.93% | 4.05% | |||
| Average Diluted Shares Outstanding | 0.93% | 4.05% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||